E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors

LESSONS LEARNED. Rate of progression‐free survival at a particular point in time, i.e., a landmark analysis, is a difficult endpoint for a heterogenous malignancy such as neuroendocrine cancer. Landmark analyses can also be complicated by evolution in the standard of care during the conduct of a cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Lubner, Sam, Feng, Yang, Mulcahy, Mary, O'Dwyer, Peter, Giang, Guang‐Yu, Hinshaw, J. Louis, Deming, Dustin, Klein, Leonard, Teitelbaum, Ursina, Payne, Jennifer, Engstrom, Paul, Stella, Philip, Meropol, Neal, Benson, Al
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192662/
https://www.ncbi.nlm.nih.gov/pubmed/29853660
http://dx.doi.org/10.1634/theoncologist.2018-0294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192662/
https://www.ncbi.nlm.nih.gov/pubmed/29853660
http://dx.doi.org/10.1634/theoncologist.2018-0294

Ejemplares similares